Alginate-based Adjuvant Development

Alginate-based Adjuvant Development

Particulate systems made of biopolymers have good properties and are used as carriers for adjuvant and vaccine delivery. CD BioGlyco is a leader in alginate-based adjuvant development, including alginate nano-aggregates development, alginate nanocapsules development, and alginate nanospheres development.

Alginate Adjuvant

Alginate is a natural, biodegradable, and mucoadhesive anionic polymer derived from the cell walls of marine brown algae. It is composed of β-D-mannuronic acid and α-L-guluronic acid linked linearly by 1,4-glycosidic bonds. Alginates are commonly used as therapeutic adjuvants, drug carriers, and bioscaffolds, and help the immune system activate cytotoxic T cells to fight tumors. For example, sodium alginate is used to prepare micro- or nano-particles as vaccine delivery systems. Alginate nanoparticles with hydrophilic carriers prolong antigen release and enhance immunogenicity compared to conventional vaccines. Therefore, alginate nanoparticles are regarded as a promising adjuvant and vaccine delivery system.

Preparation Methods of Alginate Nanoparticles

Researchers have discovered that alginate nanoparticles are a promising vaccine delivery system and adjuvant. Based on the importance of alginate nanoparticles in vaccines, researchers have developed two common methods for the preparation of alginate nanoparticles. One approach is to form alginate nano-aggregates in aqueous solutions or to form alginate nanocapsules on oil droplet interfaces by self-assembly and complexation. Another preparation method is to form alginate nanospheres by emulsification of alginate-in-oil and gelation of the outer or inner part of the alginate emulsion droplets.

Nano-aggregate, nanocapsule, and nanosphere.Fig.1 Nano-aggregate, nanocapsule, and nanosphere. (Paques, 2014)

Alginate Adjuvant Development Services

Alginate has shown the potential for vaccine development. CD BioGlyco is a leader in Carbohydrate-based Vaccine Adjuvant Development, and our strategies for alginate-based adjuvant development include but are not limited to:

  • Alginate nano-aggregates development: poly-L-lysine-alginate nano-aggregates, chitosan-alginate nano-aggregates, silica-alginate nano-aggregates, and cisplatin-alginate nano-aggregates.
  • Alginate nanocapsules development: alginate nanocapsules and chitosan-alginate nanocapsules.
  • Alginate nanospheres development: bovine serum albumin-alginate nanospheres, dextran-alginate nanospheres, and chitosan-alginate nanospheres.

Applications of Alginate Adjuvant

  • As a subcutaneous adjuvant for Hepatitis B surface antigen
  • As an antigen delivery system and adjuvant for leishmaniasis
  • As a carrier and adjuvant for cancer immunotherapy
  • As a natural adjuvant for cholera vaccine

CD BioGlyco is a recognized leader in the development of carbohydrate adjuvants worldwide. Our professional Glyco™ Vaccine Development Platform and first-class development technology have been recognized by scientists. We are very pleased to share our knowledge and experience. If you have needs in alginate-based adjuvant development, please feel free to contact us. We are looking forward to being your indispensable research assistant in the field of adjuvant development.


  1. Paques, J.P.; et al. Preparation methods of alginate nanoparticles. Advances in colloid and interface science. 2014, 209:163-171.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.